دورية أكاديمية
أعرض في EDS

Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?

التفاصيل البيبلوغرافية
العنوان: Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?
المؤلفون: Thirasastr P; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Sutton TL; Division of Surgical Oncology, OHSU Knight Cancer Institute, Oregon Health & Science University School of Medicine, Portland, OR 97239, USA., Joseph CP; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Lin H; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Amini B; Department of Musculoskeletal Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Mayo SC; Division of Surgical Oncology, OHSU Knight Cancer Institute, Oregon Health & Science University School of Medicine, Portland, OR 97239, USA., Araujo D; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Benjamin RS; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Conley AP; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Livingston JA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ludwig J; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Patel S; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ratan R; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ravi V; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zarzour MA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Nassif Haddad EF; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Nakazawa MS; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zhou X; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Heinrich MC; Cell and Developmental Biology, OHSU Knight Cancer Institute, Oregon Health & Science University School of Medicine, Portland, OR 97239, USA., Somaiah N; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
المصدر: Cancers [Cancers (Basel)] 2024 Feb 23; Vol. 16 (5). Date of Electronic Publication: 2024 Feb 23.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Ripretinib and avapritinib have demonstrated activity in the late-line treatment of gastrointestinal stomal tumors (GISTs). We investigated whether patients previously treated with ripretinib benefit from avapritinib, and vice versa. Patients diagnosed with metastatic/unresectable GIST and treated with both drugs at two institutions in 2000-2021 were included. Patients were grouped by drug sequence: ripretinib-avapritinib (RA) or avapritinib-ripretinib (AR). Radiographic response was evaluated using RECIST 1.1. Kaplan-Meier and log-rank tests were used to compare time-to-progression (TTP) and overall survival (OS). Thirty-four patients (17 per group) were identified, with a median age of 48 years. The most common primary site was the small bowel (17/34, 50%), followed by the stomach (10/34, 29.4%). Baseline characteristics and tumor mutations were not significantly different between groups. Response rates (RRs) for ripretinib were 18% for RA and 12% for AR; RRs for avapritinib were 12% for AR and 18% for RA. Median TTPs for ripretinib were 3.65 months (95%CI 2-5.95) for RA and 4.73 months (1.87-15.84) for AR. Median TTPs for avapritinib were 5.39 months (2.86-18.99) for AR and 4.11 months (1.91-11.4) for RA. Median OS rates following RA or AR initiation were 29.63 (95%CI 13.8-50.53) and 33.7 (20.03-50.57) months, respectively. Both ripretinib and avapritinib were efficacious in the late-line treatment of GIST, with no evidence that efficacy depended on sequencing.
References: Oncogene. 2017 Jun 29;36(26):3661-3672. (PMID: 28192400)
Eur J Cancer. 2003 Sep;39(14):2006-11. (PMID: 12957454)
Lancet Oncol. 2020 Jul;21(7):923-934. (PMID: 32511981)
Front Oncol. 2023 May 18;13:1180795. (PMID: 37274264)
Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986498. (PMID: 33473249)
Oncologist. 2021 Apr;26(4):e639-e649. (PMID: 33453089)
Clin Cancer Res. 2006 Mar 15;12(6):1743-9. (PMID: 16551858)
Clin Cancer Res. 2019 Jan 15;25(2):609-618. (PMID: 30274985)
J Hematol Oncol. 2021 Jan 5;14(1):2. (PMID: 33402214)
Eur J Cancer. 2021 Sep;155:236-244. (PMID: 34391056)
Cancer Cell. 2019 May 13;35(5):738-751.e9. (PMID: 31085175)
Nat Med. 2021 Dec;27(12):2183-2191. (PMID: 34873347)
Lancet. 2013 Jan 26;381(9863):295-302. (PMID: 23177515)
Expert Rev Gastroenterol Hepatol. 2023 Feb;17(2):119-127. (PMID: 36644853)
N Engl J Med. 2001 Apr 5;344(14):1052-6. (PMID: 11287975)
Lancet Oncol. 2020 Jul;21(7):935-946. (PMID: 32615108)
J Gastrointest Oncol. 2017 Jun;8(3):466-473. (PMID: 28736634)
Oncologist. 2021 Apr;26(4):e622-e631. (PMID: 33301227)
Lancet. 2006 Oct 14;368(9544):1329-38. (PMID: 17046465)
J Clin Oncol. 2022 Dec 1;40(34):3918-3928. (PMID: 35947817)
Lab Invest. 2004 Jul;84(7):874-83. (PMID: 15146165)
Clin Cancer Res. 2024 Feb 16;30(4):719-728. (PMID: 38032349)
Cancers (Basel). 2023 Feb 27;15(5):. (PMID: 36900287)
Onco Targets Ther. 2016 Dec 15;9:7573-7582. (PMID: 28008275)
Sci Transl Med. 2017 Nov 1;9(414):. (PMID: 29093181)
Cancer Chemother Rep. 1966 Mar;50(3):163-70. (PMID: 5910392)
Cancer. 2010 Apr 15;116(8):1847-58. (PMID: 20166214)
Nat Commun. 2024 Jan 2;15(1):63. (PMID: 38167404)
معلومات مُعتمدة: I01 BX005358 United States BX BLRD VA; P30 CA016672 United States CA NCI NIH HHS; R21 CA263400 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: avapritinib; gastrointestinal stomal tumor; ripretinib
تواريخ الأحداث: Date Created: 20240313 Latest Revision: 20240316
رمز التحديث: 20240316
مُعرف محوري في PubMed: PMC10931337
DOI: 10.3390/cancers16050904
PMID: 38473266
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers16050904